125 related articles for article (PubMed ID: 38462673)
1. Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
Ngo HX; Xu AY; Velásquez GE; Zhang N; Chang VK; Kurbatova EV; Whitworth WC; Sizemore E; Bryant K; Carr W; Weiner M; Dooley KE; Engle M; Dorman SE; Nahid P; Swindells S; Chaisson RE; Nsubuga P; Lourens M; Dawson R; Savic RM
Clin Infect Dis; 2024 Jun; 78(6):1680-1689. PubMed ID: 38462673
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
[TBL] [Abstract][Full Text] [Related]
3. Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India.
Aruldhas BW; Hoglund RM; Ranjalkar J; Tarning J; Mathew SK; Verghese VP; Bose A; Mathew BS
Br J Clin Pharmacol; 2019 Mar; 85(3):644-654. PubMed ID: 30588647
[TBL] [Abstract][Full Text] [Related]
4. A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.
Schipani A; Pertinez H; Mlota R; Molyneux E; Lopez N; Dzinjalamala FK; van Oosterhout JJ; Ward SA; Khoo S; Davies G
Br J Clin Pharmacol; 2016 Apr; 81(4):679-87. PubMed ID: 26613187
[TBL] [Abstract][Full Text] [Related]
5. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis.
Te Brake L; Dian S; Ganiem AR; Ruesen C; Burger D; Donders R; Ruslami R; van Crevel R; Aarnoutse R
Int J Antimicrob Agents; 2015 May; 45(5):496-503. PubMed ID: 25703312
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis.
Abulfathi AA; Decloedt EH; Svensson EM; Diacon AH; Donald P; Reuter H
Clin Pharmacokinet; 2019 Sep; 58(9):1103-1129. PubMed ID: 31049868
[TBL] [Abstract][Full Text] [Related]
8. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Turkova A; Waalewijn H; Chan MK; Bollen PDJ; Bwakura-Dangarembizi MF; Kekitiinwa AR; Cotton MF; Lugemwa A; Variava E; Ahimbisibwe GM; Srirompotong U; Mumbiro V; Amuge P; Zuidewind P; Ali S; Kityo CM; Archary M; Ferrand RA; Violari A; Gibb DM; Burger DM; Ford D; Colbers A;
Lancet HIV; 2022 Sep; 9(9):e627-e637. PubMed ID: 35868341
[TBL] [Abstract][Full Text] [Related]
9. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
[TBL] [Abstract][Full Text] [Related]
10. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.
Heinrich N; Dawson R; du Bois J; Narunsky K; Horwith G; Phipps AJ; Nacy CA; Aarnoutse RE; Boeree MJ; Gillespie SH; Venter A; Henne S; Rachow A; Phillips PP; Hoelscher M; Diacon AH; ;
J Antimicrob Chemother; 2015 May; 70(5):1558-66. PubMed ID: 25630641
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.
Garcia-Prats AJ; Schaaf HS; Draper HR; Garcia-Cremades M; Winckler J; Wiesner L; Hesseling AC; Savic RM
PLoS Med; 2019 Apr; 16(4):e1002789. PubMed ID: 31039153
[TBL] [Abstract][Full Text] [Related]
12. Rifampicin Can Be Given as Flat-Dosing Instead of Weight-Band Dosing.
Susanto BO; Svensson RJ; Svensson EM; Aarnoutse R; Boeree MJ; Simonsson USH
Clin Infect Dis; 2020 Dec; 71(12):3055-3060. PubMed ID: 31867594
[TBL] [Abstract][Full Text] [Related]
13. Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis.
Svensson RJ; Niward K; Davies Forsman L; Bruchfeld J; Paues J; Eliasson E; Schön T; Simonsson USH
Br J Clin Pharmacol; 2019 Oct; 85(10):2341-2350. PubMed ID: 31269277
[TBL] [Abstract][Full Text] [Related]
14. The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.
Svensson EM; Svensson RJ; Te Brake LHM; Boeree MJ; Heinrich N; Konsten S; Churchyard G; Dawson R; Diacon AH; Kibiki GS; Minja LT; Ntingiya NE; Sanne I; Gillespie SH; Hoelscher M; Phillips PPJ; Simonsson USH; Aarnoutse R
Clin Infect Dis; 2018 Jun; 67(1):34-41. PubMed ID: 29917079
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol.
Mlotha R; Waterhouse D; Dzinjalamala F; Ardrey A; Molyneux E; Davies GR; Ward S
J Antimicrob Chemother; 2015; 70(6):1798-803. PubMed ID: 25759035
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
Verhagen LM; López D; Hermans PW; Warris A; de Groot R; García JF; de Waard JH; Aarnoutse RE
Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704
[TBL] [Abstract][Full Text] [Related]
17. Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.
Denti P; Wasmann RE; van Rie A; Winckler J; Bekker A; Rabie H; Hesseling AC; van der Laan LE; Gonzalez-Martinez C; Zar HJ; Davies G; Wiesner L; Svensson EM; McIlleron HM
Clin Infect Dis; 2022 Aug; 75(1):141-151. PubMed ID: 34665866
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
19. Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin.
Susanto BO; Svensson EM; Te Brake L; Aarnoutse RE; Boeree MJ; Simonsson USH;
Int J Antimicrob Agents; 2023 Jun; 61(6):106813. PubMed ID: 37037318
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial.
Cross GB; Sari IP; Kityo C; Lu Q; Pokharkar Y; Moorakonda RB; Thi HN; Do Q; Dalay VB; Gutierrez E; Balanag VM; Castillo RJ; Mugerwa H; Fanusi F; Kwan P; Chew KL; Paton NI;
Lancet Infect Dis; 2023 Jul; 23(7):847-855. PubMed ID: 36966799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
